Decreased Flow-mediated Dilatation in Patients with Systemic Lupus Erythematosus: a Meta-analysis
Overview
Pathology
Authors
Affiliations
Premature atherosclerosis, the hallmark of cardiovascular diseases, has been found to be a significant cause of late deaths in systemic lupus erythematosus (SLE) patients. Therefore, early identification of atherosclerosis before the overt disease is curial for the management program of SLE. Flow-mediated dilatation (FMD%) is a reliable, noninvasive, easy to use, reproducible, and pathogenically relevant index for early atherosclerosis. In recent years, a number of studies have been performed to compare the mean FMD% difference between patients with SLE and healthy controls. However, these studies have shown inconclusive or even contradictory findings. In this study, to derive a more precise comparison of FMD% difference between SLE patients and healthy controls, a meta-analysis was performed. Databases were searched to identify all available studies comparing FMD% between SLE patients and healthy controls. The study eligibility criteria were cohort or case-control studies with data on both patients diagnosed with SLE and healthy controls, and use of high-resolution ultrasonography to detect FMD. Random effect meta-analysis was conducted to evaluate the overall mean FMD% difference between the two groups. Publication bias was detected by funnel plot and Egger's test. Meta-regression analysis was performed to investigate the potential influencing factors on FMD% difference. Of the 434 articles initially identified, 22 were finally included in the meta-analysis. Compared to healthy controls, SLE patients had significantly lower FMD% (standardized mean difference, -1.19; 95% CI, -1.63, -0.74; P < 0.001). There was significant heterogeneity among these studies (I (2) = 94.3%, P < 0.001), which was mainly due to variations in disease duration of SLE patients. The funnel plot showed a skewed shape, indicating a marked publication bias, which was further supported by the Egger's test (P = 0.006). However, after the correction for potential publication bias by using the trim-and-fill method, the main results for all studies combined were still significant (P < 0.001). Taken together, these findings support the current evidence on a higher cardiovascular burden in SLE and support using FMD% as a surrogate for premature atherosclerosis in SLE patients.
Inflammation and Arterial Stiffness as Drivers of Cardiovascular Risk in Kidney Disease.
Lo Cicero L, Lentini P, Sessa C, Castellino N, DAnca A, Torrisi I Cardiorenal Med. 2024; 15(1):29-40.
PMID: 39631378 PMC: 11844711. DOI: 10.1159/000542965.
Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician.
Semalulu T, Tago A, Zhao K, Tselios K Immunotargets Ther. 2023; 12:175-186.
PMID: 38089168 PMC: 10714964. DOI: 10.2147/ITT.S377076.
Endothelial dysfunction in patients with systemic sclerosis.
Pacholczak-Madej R, Kuszmiersz P, Bazan-Socha S, Kosalka-Wegiel J, Iwaniec T, Zareba L Postepy Dermatol Alergol. 2020; 37(4):495-502.
PMID: 32994769 PMC: 7507157. DOI: 10.5114/ada.2019.83501.
Zanoli L, Briet M, Empana J, Cunha P, Maki-Petaja K, Protogerou A J Hypertens. 2020; 38(9):1682-1698.
PMID: 32649623 PMC: 7610698. DOI: 10.1097/HJH.0000000000002508.
Endothelial dysfunction in patients with granulomatosis with polyangiitis: a case-control study.
Pacholczak R, Bazan-Socha S, Iwaniec T, Zareba L, Kielczewski S, Walocha J Rheumatol Int. 2018; 38(8):1521-1530.
PMID: 29850964 PMC: 6060787. DOI: 10.1007/s00296-018-4061-x.